CD19 Antibody (CB19) - BSA Free

Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - CD19 antibody (CB19) was tested in Non-Hodgkin's lymphoma cells at 1:200 dilution. Green: Alexa Flour 488. Image from verified customer review.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on Ramos cells with CD19 Antibody (CB19) NBP2-26646 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.

Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - The CD19 (CB19) antibody was tested in Daudi cells at a 1:40 dilution against Dylight 488 (Green). Actin and nuclei were counterstained against Phalloidin 568 (Red) and DAPI (Blue), respectively.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Surface staining of 10^6 human lymphocytes using 0.2 ug of CD19 antibody (red) and isotype control (green). Cell surface staining kit was used for this test.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the FITC conjugate of NBP2-25196. Staining of CD19 in 10^6 human lymphocytes using 10 ul (0.25 ug) of this antibody. Shaded histogram represents cells without antibody; green represents isotype control ; red represents anti-CD19 antibody.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the PE conjugate of NBP2-25196. Staining of CD19 in 1x10^6 human PBMC using 10 ul (0.25 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-25196. Staining of human PBMC. Image from verified customer review.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the DyLight 405 conjugate of NBP2-25196. Staining of CD19 in human PBMCs using anti-CD19 antibody. Image from verified customer review.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with TACI/TNFRSF13B/CVID (1A1) antibody NB600-1189PE and a matched isotype control. Cells were incubated in an antibody dilution of 2 ug/mL for 20 minutes at room temperature. A co-stain was performed with NBP2-25196AF647.

Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with CD9 (HI9a) antibody NB100-77915AF647 and a matched isotype control NBP2-27287AF488. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. A co-stain was performed with NBP2-26646.

• Reactivity: Hu, Mu
• Applications: WB, Flow, Func, ICC/IF, CyTOF-ready
• Clone: CB19
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

CD19 Antibody (CB19) - BSA Free Summary

• Immunogen: Intact normal human B cell cells were used as immunogen to generate the CB19 clone.
• Epitope: The exact CD19 epitope recognized by the antibody has not been mapped and is unknown.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CD19
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.2 ug/10^6 cells
  • Immunocytochemistry/ Immunofluorescence 1:25-1:100
  • In vitro assay reported in scientific literature (PMID 9576485)
  • Western Blot reported in scientific literature (PMID 17327405)
• Application Notes: This antibody is CyTOF ready.

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 27532872).

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein G purified

Alternate Names for CD19 Antibody (CB19) - BSA Free

• B4
• B-lymphocyte antigen CD19
• B-lymphocyte surface antigen B4
• CD19 antigen
• CD19 molecule
• CD19
• CVID3
• Differentiation antigen CD19
• Leu-12
• MGC12802
• T-cell surface antigen Leu-12

Background

CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, is a type 1 transmembrane glycoprotein belonging to immunoglobulin (Ig) subfamily that serves as a biomarker for normal and neoplastic B cells (1,2). CD19 is a co-receptor for the B cell receptor (BCR) signaling complex and has a critical role in regulating B cell signaling and immune response (1,2). The CD19 protein contains an extracellular N-terminus containing two C2 Ig-like domains separated by a helical non-Ig domain, a single pass transmembrane domain, and a highly conserved cytoplasmic C-terminal domain (1,2). The human CD19 protein, encoded by the CD19 gene located on chromosome 16p11.2, is 556 amino acids (aa) in length with a calculated theoretical molecular weight (MW) of 61 kDa and an observed molecular weight of 95 kDa (1-3). CD19 associates with other molecules - CD21, CD81, and CD225 - to form the BCR co-complex, also called the CD19 complex, through CD21 binding to the complement C3d complex (1-3). Complement C3d bridges the BCR with the CD19 complex into lipid rafts of the plasma membrane (1-3). CD19 is capable of modulating B cell development through both BCR-dependent and -independent signaling (1-3). Upon BCR activation, the tyrosine residues of CD19's cytoplasmic tail recruits multiple kinases including Lyn, Vav, and PI3K, amplifying BCR-mediated immune signaling and B cell activation (1-3).

Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).

References

1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36

2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010

3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017

4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208

5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445

6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CD19 Antibody (NBP2-25196)(12)

Publications using NBP2-25196

• Jun Ochiai, Larakaye Villanueva, Hope Niihara, Yutaka Niihara, Joan Oliva Posology and Serum-/Xeno-Free Engineered Adipose Stromal Cells Cell Sheets Frontiers in Cell and Developmental Biology 2022-04-26 [PMID: 35557946]
• Holla S, Prakhar P, Singh V et al. MUSASHI-Mediated Expression of JMJD3, a H3K27me3 Demethylase, Is Involved in Foamy Macrophage Generation during Mycobacterial Infection PLoS Pathog. PLoS Pathog. 2016-08-01 [PMID: 27532872] (Mouse)
  
  Details:
  This citation used the PE version of this antibody.
• Deaglio S, Vaisitti T, Billington R et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells Blood. 2007-06-15 [PMID: 17327405] (ICC/IF, WB, Human)
• Deaglio S, Vaisitti T, Bergui L et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival Blood. 2005-04-15 [PMID: 15613544] (ICC/IF, FLOW, Human)
• Deaglio S, Capobianco A, Bergui L et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells Blood. 2003-09-15 [PMID: 12763926] (ICC/IF, FLOW, Human)
• Musso T, Deaglio S, Franco L et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines J Leukoc Biol. 2001-04-01 [PMID: 11310847] (Human)
• Deaglio S, Canella D, Baj G et al. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells Leuk Res. 2001-03-01 [PMID: 11226519]
• Zilber MT, Gregory S, Mallone R et al. CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation Proc Natl Acad Sci U S A. 2000-03-14 [PMID: 10706632] (Human)
• Morra M, Zubiaur M, Terhorst C et al. CD38 is functionally dependent on the TCR/CD3 complex in human T cells FASEB J. 1998-05-01 [PMID: 9576485] (In vitro, Human)
• Deaglio S, Morra M, Mallone R et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member J Immunol. 1998-01-01 [PMID: 9551996] (FLOW, Human)
• Sorensen EM Plasma-derived exosomes as potential biomarkers for pediatric acute leukemia. Thesis 2020-01-01 (WB, Human)
  
  Details:
  Exosomes from human plasma samples underwent Western blot analysis.
• Wang X, Nakamoto T, Dulinska-Molak I. Regulating the stemness of mesenchymal stem cells by tuning micropattern features. J Mater Chem B 2020-04-09 [PMID: 32262807]

Review for CD19 Antibody (NBP2-25196) (1)

Average Rating: 5

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer ICC Human 12/15/2021

Summary

• Application: Immunocytochemistry
• Sample Tested: Non-Hodgkin's lymphoma cells
• Species: Human
• Lot: CB19

Bioinformatics

• Gene Symbol: CD19
• Entrez:
  • 930(Human)
• Uniprot:
  • P15391(Human)